All Episodes

Eileen M. O'Reilly, MD, FASCO - Hope Is on the Horizon: Anticipating Novel Treatment Approaches in Advanced Pancreatic Cancer

Luis Querol, MD, PhD - CIDP at a Crossroads: Addressing the Burden of Suboptimal Care and the Need for Therapeutic Advancement

Amarnath Challapalli, MBBS, MD (RT), MRCP, FRCR, PhD, FRCP / Amer Durrani, FRCS (Plast) - Partnering With Patients in High-Risk CSCC: Redefining the Surgical Paradigm to Optimise Clinical and Patient Outcomes

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Irina Turchin, MD, FRCPC, DABD / Hélène Veillette, MD, FRCPC - On the Case: Practical Insights to Individualize Biologic Treatment in Moderate-to-Severe Hidradenitis Suppurativa

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions

Alice YY Cheng, MD, FRCPC - Elevating Care for T2D: Translating the Latest Advances on Incretin-Based Therapies to Practice

Krista Noonan, BSc, MD, FRCPC / Elizabeth R. Plimack, MD, MS, FASCO - Redefining the Standards of Care in RCC: Expert Insights to Translate Recent Advances to Clinical Practice

Denise Black, MD, FRCSC / Marla Shapiro, C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, MSCP - Navigating the Menopause Transition With Your Patients: Experts Answer Key Questions

Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Mariana Castells, MD, PhD - Rare But Highly Significant: Best Practices in Recognizing and Diagnosing Systemic Mastocytosis

Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC

Olga Kordonouri, MD - Confronting the Silent Progression of Type 1 Diabetes: Rationales and Roadmaps for Early Detection and Proactive Intervention

Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma

Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers

Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Julie Stakiw, MD, FRCPC - Clinical Conundrums in CLL: When to Use Continuous Versus Fixed-Duration Treatment

Brandon M. Meyers, MSc, MD, FRCPC - Raising the Bar in Advanced Hepatocellular Carcinoma Care: Insights to Optimize First-Line Treatment

Michael P. Chu, MD - Chimeric Antigen Receptor T Cells: A New Step in Improving Multiple Myeloma Management

Gerald Prager, MD - Don't Leave a Drug on the Table: Maximising Use and Benefits of Later-Line Treatments for Advanced Colorectal Cancer

Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates

Martin O. Savage, MB, BChir, MA, MD, FRCP, FRCPCH - Taking a Longer Look at Your Patient With Short Stature: Could it Be SPIGFD?

Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns

Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch

Luke Stephen Prockter Moore, FRCP, FRCPath, PhD - A Cohesive Multidisciplinary Approach to Antimicrobial Stewardship: Joining the Dots on Rapid Diagnostic Testing

Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?

Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit

Starting Strong at First Relapse in Multiple Myeloma: Insights to Guide Treatment Selection in Lenalidomide-Refractory Patients

Strategies to Guide Treatment Selection in Relapsed/Refractory AML: An Expert Discussion

Catching a Break in Fibrodysplasia Ossificans Progressiva: Case-Based Approaches to Improve Diagnosis and Management

Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors

Treatment of Metastatic Triple-Negative Breast Cancer: Progress and Perspective

Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care

Immunotherapy Combinations for First-Line Advanced NSCLC Treatment: Clinical Insights on Current and Emerging Options